ISDA

Entry Detail

PDB ID:

7RFU

Keywords:

HYDROLASE/INHIBITOR

Title:

Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2021-07-14

Release Date:

2021-11-10

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.27

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:3C-like proteinase
Chain IDs:A
Chain Length:306
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTD1 Pfam ID:PF05409 EC:2.7.7.48

Ligand Molecules

4YG

Primary Citation

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19.

Owen, D.R, Allerton, C.M.N, Anderson, A.S, Aschenbrenner, L, Avery, M, Berritt, S, Boras, B, Cardin, R.D, Carlo, A, Coffman, K.J, Dantonio, A, Di, L, Eng, H, Ferre, R, Gajiwala, K.S, Gibson, S.A, Greasley, S.E, Hurst, B.L, Kadar, E.P, Kalgutkar, A.S, Lee, J.C, Lee, J, Liu, W, Mason, S.W, Noell, S, Novak, J.J, Obach, R.S, Ogilvie, K, Patel, N.C, Pettersson, M, Rai, D.K, Reese, M.R, Sammons, M.F, Sathish, J.G, Singh, R.S.P, Steppan, C.M, Stewart, A.E, Tuttle, J.B, Updyke, L, Verhoest, P.R, Wei, L, Yang, Q, Zhu, Y.Show

Science 374 1586 1593 (2021)

PMID: 34726479 DOI: 10.1126/science.abl4784

Abstact

The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.

Legend

Protein

Chemical

Disease

Primary Citation of related structures